Abstract 5864
Background
Cancer is considered a traumatic event that can lead to post-traumatic stress disorder. Significant changes are taking place in the life, body image, lifestyle and social life of the individual diagnosed with cancer. Therefore, they are faced with a psychological and physiological difficult process. In the researches, it was found that the attachment styles that individuals will experience in their lifelong relationships are one of the important predictors of psychological resilience. The aim of our study is to examine the relationship between psychological resilience and adult attachment styles among cancer patient individuals receiving chemotherapy.
Methods
A total of 391 volunteer patients receiving chemotherapy were included from Dr. A.Y. Ankara Oncology Research and Training Hospital and Ankara Güven Hospital in the study. The inventories used in the data collection phase of the study are Relationship Scales Questionnaire, Resilience Scale for Adults and a personal information form that is produced by researcher. Datasare analyzed with SPSS 23.00.
Results
In our results, 285 (73%) of the patients were female and the median age was 53 (20-83). The median endurance score was 130 (49-165). The patients were divided into median values to be less resistant and resistant. The age, gender, marital status, working status, educational status, economic status, who they experienced, who they grew up with, their social support, trust in chemotherapy and dominant attachment styles were compared with univariate analysis. there were four style of attachments; secure, avoidant, fearful, preoccupied. Secure attachment was at half of patients (n = 191,48.8%) while avoidant attachment was at 159 (40.6%) patients. The other attachment styles were seen significantly less.
As a result of multivariate analysis, the patient’s social support is moderate or bad; lack of confidence in chemotherapy, the presence of avoidant or fearful attachment was found to be independent negative factors affecting the resilience of the patient.
Conclusions
Avoidant and fearful attachment have a significant negative impact on the resilience of the patients receiving chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fatma Bugdayci Basal.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1357 - Upfront atezolizumab chemoimmunotherapy-associated Immune-related adverse events in patients with advanced non-small cell lung cancer
Presenter: Francis Mogollon-Duffo
Session: Poster Display session 1
Resources:
Abstract
1851 - Nivolumab-induced and radiation recall pneumonitis in patients with non-small cell lung cancer: a multicenter real world analysis of 669 patients
Presenter: Nobuaki Mamesaya
Session: Poster Display session 1
Resources:
Abstract
851 - Retrospective analysis of immunotherapy prognostic scores in advanced NSCLC at Nottingham University Hospitals (UK)
Presenter: Cristina Lopez Escola
Session: Poster Display session 1
Resources:
Abstract
3639 - Applicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC)
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 1
Resources:
Abstract
2950 - Delayed Onset Immune Related Adverse Effects (IRAEs) of Pembrolizumab in Non-Small Cell Lung Cancer
Presenter: Haixi Yan
Session: Poster Display session 1
Resources:
Abstract
3659 - Clinical implication of multiplex IHC and serologic biomarkers on Hyperprogression in NSCLC patients receiving Immune checkpoint blockers in real world.
Presenter: Joori Kim
Session: Poster Display session 1
Resources:
Abstract
4882 - Local ablative treatment and treatment beyond progression for oligo-progression in stage IV non-small cell lung cancer after tumor response to anti-PD1 treatment
Presenter: Florian Guisier
Session: Poster Display session 1
Resources:
Abstract
1358 - Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)
Presenter: Francis Mogollon-Duffo
Session: Poster Display session 1
Resources:
Abstract
2170 - Prognostic Impact of Metastatic Sites for Pembrolizumab Efficacy as First-line therapy in Patients with PD-L1 tumor proportion score (TPS) ≥ 50% Advanced Non–Small Cell Lung Cancer: A Retrospective Multicenter Study
Presenter: Hayato Kawachi
Session: Poster Display session 1
Resources:
Abstract
3051 - Impact of visceral fat area as independent predictive factor in patients with advanced non-small cell lung cancer treated with nivolumab
Presenter: Yuki Sato
Session: Poster Display session 1
Resources:
Abstract